337 related articles for article (PubMed ID: 17207305)
21. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
Patel GW; Roderman N; Gehring H; Saad J; Bartek W
Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
[TBL] [Abstract][Full Text] [Related]
24. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
[TBL] [Abstract][Full Text] [Related]
25. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.
Hodder RV; Hall R; Russell JA; Fisher HN; Lee B
Crit Care; 2009; 13(3):R78. PubMed ID: 19457240
[TBL] [Abstract][Full Text] [Related]
26. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
[TBL] [Abstract][Full Text] [Related]
27. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
Rowan KM; Welch CA; North E; Harrison DA
Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
[TBL] [Abstract][Full Text] [Related]
28. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.
Vincent JL; O'Brien J; Wheeler A; Wittebole X; Garg R; Trzaskoma BL; Sundin DP
Crit Care; 2006; 10(3):R74. PubMed ID: 16684364
[TBL] [Abstract][Full Text] [Related]
29. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
31. Is worsening multiple organ failure the cause of death in patients with severe sepsis?
Vincent JL; Nelson DR; Williams MD
Crit Care Med; 2011 May; 39(5):1050-5. PubMed ID: 21317650
[TBL] [Abstract][Full Text] [Related]
32. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.
Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z
Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
34. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
Dhainaut JF;
Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
[TBL] [Abstract][Full Text] [Related]
35. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
Short MA; Schlichting D; Qualy RL
Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
[TBL] [Abstract][Full Text] [Related]
37. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
38. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
[TBL] [Abstract][Full Text] [Related]
39. A prospective, observational study of Xigris Use in the United States (XEUS).
Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB;
J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433
[TBL] [Abstract][Full Text] [Related]
40. Single-dose etomidate is not associated with increased mortality in ICU patients with sepsis: analysis of a large electronic ICU database.
McPhee LC; Badawi O; Fraser GL; Lerwick PA; Riker RR; Zuckerman IH; Franey C; Seder DB
Crit Care Med; 2013 Mar; 41(3):774-83. PubMed ID: 23318491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
